Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

E

Hosseinipour MC, Bisson GP, Miyahara S, et al. "Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial." Lancet. 2016;387(10024):1198-209.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
Labo N, Miley W, Benson CA, Campbell TB, Whitby D. "Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy." AIDS. 2015;29(10):1217-25.
Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M. "Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure." PLoS Pathog.. 2011;7(2):e1001303.
Schouten JThomas, Schiffer JT. "Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2012;60(1):68-71.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.
Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA. "Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095." J Am Stat Assoc. 2012;107(498):542-554.
Sattler FR, Rajicic N, Mulligan K, et al. "Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial." Am. J. Clin. Nutr.. 2008;88(5):1313-21.
Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. "Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption." J. Acquir. Immune Defic. Syndr.. 2012;61(1):19-22.
Li B, Verma SS, Veturi YC, et al. "Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression." Pac Symp Biocomput. 2018;23:448-459.
Luetkemeyer AF, Kendall MA, Wu X, et al. "Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB." J. Clin. Microbiol.. 2014;52(4):1052-9.
Luetkemeyer AF, Firnhaber C, Kendall MA, et al. "Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings." Clin. Infect. Dis.. 2016;62(9):1081-8.
Jacobson JM, R Bucy P, Spritzler J, et al. "Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068." J. Infect. Dis.. 2006;194(5):623-32.
Henrich TJ, Tsibris AMN, Lewine NRP, et al. "Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate." J. Acquir. Immune Defic. Syndr.. 2010;55(4):420-7.
Manasa J, Varghese V, Pond SLKosakovs, et al. "Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors." Sci Rep. 2017;7(1):11559.
Blanchard-Horan C, Stocker V, Moran L, et al. "Examining the challenges and solutions to the implementation of trials in resource-limited settings: Limited Resource Trials." Appl Clin Trials. 2012;21(1):34-42.
Harrison T, Miyahara S, Lee A, et al. "Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies." Pain Med. 2013;14(7):1039-47.
Almeida C-AM, Roberts SG, Laird R, et al. "Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responses." Vaccine. 2010;28(37):6052-7.
Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE. "Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients." HIV Clin Trials. 2012;13(2):70-82.
Dubé MP, Komarow L, Fichtenbaum CJ, et al. "Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation." Clin. Infect. Dis.. 2015;61(5):840-9.

F

Zheng L, Taiwo B, Gandhi RT, et al. "Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2014;67(2):153-60.
Andersen JW, Fass R, van der Horst C. "Factors associated with early study discontinuation in AACTG studies, DACS 200." Contemp Clin Trials. 2007;28(5):583-92.
Smurzynski M, Wu K, Schouten JT, et al. "Factors associated with remaining on initial randomized efavirenz-containing regimens." AIDS. 2013;27(12):1887-97.
Li JZ, Brumme ZL, Brumme CJ, et al. "Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial." J. Infect. Dis.. 2011;203(7):976-83.
Brehm JH, Lalama CM, Hughes MD, et al. "Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2011;56(4):344-8.
Sharif M, Daryani A, Karimi SA. "A faunistic survey of cercariae isolated from lymnaeid snails in central areas of Mazandaran, Iran." Pak. J. Biol. Sci.. 2010;13(4):158-63.
McLaren PJ, Ripke S, Pelak K, et al. "Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans." Hum. Mol. Genet.. 2012;21(19):4334-47.
Ciaranello AL, Lockman S, Freedberg KA, et al. "First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial." AIDS. 2011;25(4):479-92.
Gerber JG, Kitch DW, Fichtenbaum CJ, et al. "Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186." J. Acquir. Immune Defic. Syndr.. 2008;47(4):459-66.
Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.

Pages